AHCPR CONSIDERING FORMATION OF TECHNOLOGY ASSESSMENT CONSORTIUM
This article was originally published in The Gray Sheet
Executive Summary
AHCPR CONSIDERING FORMATION OF TECHNOLOGY ASSESSMENT CONSORTIUM composed of government, industry, academia, and health care provider representatives, Lisa Simpson, MD, a senior policy analyst in the Agency for Health Care Policy and Research, said at a Sept. 20 meeting of the National Association for Medical Equipment Services in Washington, D.C. The agency, according to Simpson, is planning to form a consortium that would "come together to conduct [technology] assessments, make available the results of those assessments, and provide technical assistance to purchasers, providers, and certified payers in judging the value" of adopting new technologies for "modified benefits packages."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.